Pilot Study of Augmentation With Aripiprazole for Incomplete Response in Late-Life Depression: Getting to Remission
Year: 2009
Type: article
Abstract: OBJECTIVE: To determine the feasibility and safety of aripiprazole augmentation for incomplete response to sequential selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) pharmacotherapy in late-life depression. METHOD: This study was a 12-week, open-label pilot study of 24 patients (recruited from June 1, 2006, to June 1, 2007) aged 65 years and above (mean, 73.9 years) diagnosed with major depressive disorder (MDD) (according to DSM-IV) who responded partially (17-item Hamilton Rating Scale for Depression [HAM-D-17] score of 11 to 15) or not at all (HAM-D score > 15) to a 16-week trial of escitalopram (up to 20 mg/day), followed by either duloxetine (up to 120 mg/day) or venlafaxine (up to 225 mg/day) for 12 weeks. Subjects received 2.5 to 15 mg per day of adjunctive aripiprazole (mean dose, 9.0 mg/day) for 12 weeks. The criterion for remission during treatment with aripiprazole was a HAM-D score < or = 10 for 2 consecutive weeks. RESULTS: Of 24 subjects in the intent-to-treat study group, 19 completed 12 weeks of augmentation with aripiprazole, 12 of 24 (50%) met criteria for remission, and 2 of 24 discontinued due to side effects (sedation, akathisia). The mean (SD) HAM-D score decreased significantly by 6.4 (5.8) points (paired t test for means, p < .01, df = 16). There were no relapses among the 12 subjects who participated in continuation treatment over a median period of 27.6 weeks. CONCLUSIONS: In older adults with MDD with incomplete response to SSRI and SNRI pharmacotherapy, aripiprazole was well tolerated, and symptoms of depression improved significantly during treatment with aripiprazole. A randomized, double-blind, placebo-controlled trial of adjunctive aripiprazole for incomplete response in late-life depression is warranted to further evaluate benefit and risk. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00177671.
DOI: 10.4088/jcp.07m03805
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: aripiprazole, geriatric depression, major depressive disorder, antidepressant augmentation, escitalopram, duloxetine, venlafaxine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, older adults, treatment remission, akathisia, drug safety and tolerability, continuation treatment
Open Access status: green
Awards: MAINTENANCE THERAPIES IN LATE LIFE DEPRESSION, 2/3-Incomplete Response in Late-Life Depression: Getting to Remission, IRC for the Study of Late-Life Mood Disorders, Geriatric Depression: Getting Better, Getting Well, Maintenance Therapies in Late-Life Depression-III, Clinical and Translational Research Training in Geriatric Mental Health
OpenAlex ID: W2106273439
